Catalysts from several late-stage projects including those from Astrazeneca, Sanofi, Allakos and Celldex aim to shake up the market.
Without full placebo data, it is hard to handicap VRDN-001’s chances in thyroid eye disease.
Nash data are due for Terns and Inventiva, as Marinus aims to expand its rare disease offering.
Key catalysts lie ahead for Amgen, Argenx, Point Biopharma and Novo Nordisk.
J&J moves FcRn towards a big new therapy area, while Bristol, Merck, Astrazeneca and Daiichi Sankyo await important oncology catalysts.
Retatrutide looks like the most powerful obesity agent yet, though side effects will need careful monitoring.